Pharmaphorum.com

The patent cliff crushed these Big Pharma companies, and now their only opportunity for sustainable growth might be to go shopping for a rival. Although we’re officially over the “patent cliff” — the multiple year period when dozens of innovator drugs...

Forecasts sales to reach $1.3 trillion by 2018 The Intellectual Property and Science business of Thomson Reuters, provider of intelligent information for businesses and professionals announced the release of the 2015 CMR Pharmaceutical R&D Factbook...

Story written by Bernard Munos at Forbes 2016 was a bummer! After years of rising FDA approvals that swelled to an all-time high of 51 new drugs in 2015, they plummeted to 22 last year—a 57% drop—down to a level not seen since 2010 (Fig 1 and 2). What...

The batting metaphor concerns cricket, not baseball... The Obama administration and members of Congress are pressing India to curb its generic medication industry. The move comes at the behest of U.S. pharmaceutical companies, which have drowned out...

It was the best of times, it was the worst of times, it was the age of wisdom, it was the age of foolishness, it was the epoch of belief, it was the epoch of incredulity, it was the season of Light, it was the season of Darkness, it was the spring of...